Skip to content

Study · Non-randomized trial · n = 33 · 2025

6 results

[Cerebrolysin with reperfusion therapy in ischemic stroke: a prospective analysis of multimodal brain imaging data from the CEREHETIS trial].

Kalinin MN, Khasanova DR

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2025

PMID40577185 (opens in a new tab)DOI10.17116/jnevro202512506184 (opens in a new tab)PepBankPUB-40577185
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In acute ischemic stroke, Cerebrolysin did not significantly change imaging parameters versus control at 24 hours.

    In plain wordsIn stroke patients, Cerebrolysin did not significantly change imaging parameters versus control at 24 hours.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeImaging parameters at 24 hours
    Study

    n = 33

    Comparator
    IVT and standard care alone
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    At 24 hours, no significant differences in imaging parameters were observed between groups.
    2 context sentences
    Summary · context
    This analysis included patients from the multimodal brain imaging subgroup of the prospective CEREHETIS trial (ISRCTN87656744) with AIS in the middle cerebral artery territory.
    Summary · context
    The intervention group (IG, n=16) received Cerebrolysin in combination with intravenous thrombolysis (IVT) and standard care, while the control group (CG, n=17) received IVT and standard care alone.
  2. 02HumanNon-randomized trialEfficacy outcome

    In acute ischemic stroke, Cerebrolysin increased axial diffusivity versus control by day 14.

    In plain wordsIn stroke patients, Cerebrolysin increased axial diffusivity versus control by day 14.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseAxial diffusivity
    Study

    n = 33

    Comparator
    IVT and standard care alone
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Predicted marginal contrast (AD)
    259.05
    Cerebrolysin versus control at day 14
    95% confidence interval for AD predicted marginal contrast
    142.19 to 375.91
    Cerebrolysin with IVT and standard care versus IVT and standard care alone; day 14
    P value for AD predicted marginal contrast
    < 0.001
    Cerebrolysin with IVT and standard care versus IVT and standard care alone; day 14

    Source sentences

    Summary
    By day 14, the IG exhibited significantly higher values of AD (predicted marginal contrast: 259.05; 95% CI 142.19-375.91; p<0.001)
    2 context sentences
    Summary · context
    This analysis included patients from the multimodal brain imaging subgroup of the prospective CEREHETIS trial (ISRCTN87656744) with AIS in the middle cerebral artery territory.
    Summary · context
    The intervention group (IG, n=16) received Cerebrolysin in combination with intravenous thrombolysis (IVT) and standard care, while the control group (CG, n=17) received IVT and standard care alone.
  3. 03HumanNon-randomized trialEfficacy outcome

    In acute ischemic stroke, Cerebrolysin increased radial diffusivity versus control by day 14.

    In plain wordsIn stroke patients, Cerebrolysin increased radial diffusivity versus control by day 14.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseRadial diffusivity
    Study

    n = 33

    Comparator
    IVT and standard care alone
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Predicted marginal contrast (RD)
    209.89
    Cerebrolysin versus control at day 14
    95% confidence interval for RD predicted marginal contrast
    106.91 to 312.87
    Cerebrolysin with IVT and standard care versus IVT and standard care alone; day 14
    P value for RD predicted marginal contrast
    < 0.001
    Cerebrolysin with IVT and standard care versus IVT and standard care alone; day 14

    Source sentences

    Summary
    By day 14, the IG exhibited significantly higher values of AD (predicted marginal contrast: 259.05; 95% CI 142.19-375.91; pp<0.001)
    2 context sentences
    Summary · context
    This analysis included patients from the multimodal brain imaging subgroup of the prospective CEREHETIS trial (ISRCTN87656744) with AIS in the middle cerebral artery territory.
    Summary · context
    The intervention group (IG, n=16) received Cerebrolysin in combination with intravenous thrombolysis (IVT) and standard care, while the control group (CG, n=17) received IVT and standard care alone.
  4. 04HumanNon-randomized trialEfficacy outcome

    In acute ischemic stroke, Cerebrolysin increased fractional anisotropy versus control by day 14.

    In plain wordsIn stroke patients, Cerebrolysin increased fractional anisotropy versus control by day 14.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseFractional anisotropy
    Study

    n = 33

    Comparator
    IVT and standard care alone
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Predicted marginal contrast (FA)
    185.13
    Cerebrolysin versus control at day 14
    95% confidence interval for FA predicted marginal contrast
    22.88 to 347.37
    Cerebrolysin with IVT and standard care versus IVT and standard care alone; day 14
    P value for FA predicted marginal contrast
    0.021
    Cerebrolysin with IVT and standard care versus IVT and standard care alone; day 14

    Source sentences

    Summary
    By day 14, the IG exhibited significantly higher values of AD (predicted marginal contrast: 259.05; 95% CI 142.19-375.91; ppp=0.021)
    2 context sentences
    Summary · context
    This analysis included patients from the multimodal brain imaging subgroup of the prospective CEREHETIS trial (ISRCTN87656744) with AIS in the middle cerebral artery territory.
    Summary · context
    The intervention group (IG, n=16) received Cerebrolysin in combination with intravenous thrombolysis (IVT) and standard care, while the control group (CG, n=17) received IVT and standard care alone.
  5. 05HumanNon-randomized trialEfficacy outcome

    In acute ischemic stroke, Cerebrolysin reduced BBB permeability versus control by day 14.

    In plain wordsIn stroke patients, Cerebrolysin reduced blood-brain barrier permeability versus control by day 14.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseBBB permeability
    Study

    n = 33

    Comparator
    IVT and standard care alone
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Predicted marginal contrast (PS)
    −1.41 mL/100 g/min
    Cerebrolysin versus control at day 14
    95% confidence interval for PS predicted marginal contrast
    −1.69 to −1.13 mL/100 g/min
    Cerebrolysin with IVT and standard care versus IVT and standard care alone; day 14
    P value for PS predicted marginal contrast
    < 0.001
    Cerebrolysin with IVT and standard care versus IVT and standard care alone; day 14

    Source sentences

    Summary
    alongside lower PS values (-1.41; 95% CI -1.69 to -1.13; p<0.001)
    2 context sentences
    Summary · context
    This analysis included patients from the multimodal brain imaging subgroup of the prospective CEREHETIS trial (ISRCTN87656744) with AIS in the middle cerebral artery territory.
    Summary · context
    The intervention group (IG, n=16) received Cerebrolysin in combination with intravenous thrombolysis (IVT) and standard care, while the control group (CG, n=17) received IVT and standard care alone.
  6. 06HumanNon-randomized trialEfficacy outcome

    In acute ischemic stroke, Cerebrolysin reduced infarct volume versus control by day 14.

    In plain wordsIn stroke patients, Cerebrolysin reduced infarct volume versus control by day 14.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseInfarct volume
    Study

    n = 33

    Comparator
    IVT and standard care alone
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Predicted marginal contrast (infarct volume)
    −6.98 mL
    Cerebrolysin versus control at day 14
    95% confidence interval for infarct volume predicted marginal contrast
    −10.13 to −3.82 mL
    Cerebrolysin with IVT and standard care versus IVT and standard care alone; day 14
    P value for infarct volume predicted marginal contrast
    < 0.001
    Cerebrolysin with IVT and standard care versus IVT and standard care alone; day 14

    Source sentences

    Summary
    and smaller infarct volume (-6.98; 95% CI -10.13 to -3.82; p<0.001).
    2 context sentences
    Summary · context
    This analysis included patients from the multimodal brain imaging subgroup of the prospective CEREHETIS trial (ISRCTN87656744) with AIS in the middle cerebral artery territory.
    Summary · context
    The intervention group (IG, n=16) received Cerebrolysin in combination with intravenous thrombolysis (IVT) and standard care, while the control group (CG, n=17) received IVT and standard care alone.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.